Education
About Us
Working with TipRanks
Follow Us
Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX
EPRX Stock Chart & Stats
$7.10
-$0.02(-0.66%)
At close: 4:00 PM EST
$7.10
-$0.02(-0.66%)
Day’s Range― - ―
52-Week Range$2.68 - $9.32
Previous CloseN/A
Volume2.60K
Average Volume (3M)148.90K
Market Cap
C$443.23M
Enterprise Value$241.61M
Total Cash (Recent Filing)C$110.43M
Total Debt (Recent Filing)C$211.59K
Price to Earnings (P/E)―
Beta0.93
Next Earnings
May 07, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding61,503,180
10 Day Avg. Volume43,828
30 Day Avg. Volume148,898
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-10.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$15.02Price Target Upside111.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.68
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And DurabilityUpdated tissue and symptom results remain consistent with earlier analyses, showing sustained symptom relief and tissue improvements after a single administration that support a long-acting therapeutic profile and potential for infrequent dosing.
Commercial Adoption PotentialAnalyst surveys and engagement with key opinion leaders indicate strong physician interest in a long-acting, localized therapy that aligns with endoscopy care and could attract patients from current topical steroid regimens.
Safety ProfileNo serious adverse events or steroid-related infections were reported and localized delivery appears to limit systemic exposure, supporting a favorable safety profile for chronic use.
Bears Say
Drug Delivery ReliabilityEarly catheter clogging in initial dosing reduced the amount of drug delivered, raising concerns about consistent administration and the need for device or process refinements.
Financial And Development Timeline UncertaintyHigher projected operating expenses and dilution from recent financing, combined with a lack of detailed clinical readouts or regulatory timelines, increase uncertainty around expected milestones and company valuation.
Limited Trial Sample SizeSmall patient numbers in dose cohorts constrain statistical confidence and leave key efficacy and durability claims unconfirmed until larger randomized trials are completed.
Eupraxia Pharmaceuticals News
EPRX FAQ
What was Eupraxia Pharmaceuticals’s price range in the past 12 months?
Eupraxia Pharmaceuticals lowest stock price was $2.68 and its highest was $9.32 in the past 12 months.
What is Eupraxia Pharmaceuticals’s market cap?
Eupraxia Pharmaceuticals’s market cap is C$443.23M.
When is Eupraxia Pharmaceuticals’s upcoming earnings report date?
Eupraxia Pharmaceuticals’s upcoming earnings report date is May 07, 2026 which is in 45 days.
How were Eupraxia Pharmaceuticals’s earnings last quarter?
Eupraxia Pharmaceuticals released its earnings results on Mar 13, 2026. The company reported -$0.299 earnings per share for the quarter, missing the consensus estimate of -$0.152 by -$0.148.
Is Eupraxia Pharmaceuticals overvalued?
According to Wall Street analysts Eupraxia Pharmaceuticals’s price is currently Undervalued.
Does Eupraxia Pharmaceuticals pay dividends?
Eupraxia Pharmaceuticals does not currently pay dividends.
What is Eupraxia Pharmaceuticals’s EPS estimate?
Eupraxia Pharmaceuticals’s EPS estimate is -0.18.
How many shares outstanding does Eupraxia Pharmaceuticals have?
Eupraxia Pharmaceuticals has 61,503,180 shares outstanding.
What happened to Eupraxia Pharmaceuticals’s price movement after its last earnings report?
Eupraxia Pharmaceuticals reported an EPS of -$0.299 in its last earnings report, missing expectations of -$0.152. Following the earnings report the stock price went down -1.867%.
Which hedge fund is a major shareholder of Eupraxia Pharmaceuticals?
Currently, no hedge funds are holding shares in EPRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eupraxia Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$15.02 (111.59% Upside)
C$15.02 (111.59% Upside)
Insider Transactions
Bought Shares
Worth C$2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.00%
12-Months-Change
Fundamentals
Return on Equity
-158.24%
Trailing 12-Months
Asset Growth
-5.79%
Trailing 12-Months
Company Description
Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis, as well as under development for treating canine and equine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
EPRX Stock 12 Month Forecast
Average Price Target
$15.02
▲(111.59% Upside)
Technical Analysis
―
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Mindbio Therapeutics Corp.
―
Ownership Overview
12.57% Insiders
19.97% Other Institutional Investors
67.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---